Pilatus Biosciences (the “Company”), a biotechnology company focused on shaping the future of cancer treatment through trailblazing First-in-class biologics focusing on metabolic checkpoints, today announces that the Company will present new preclinical data of its anti-CD36 antibody program, PLT012, at the upcoming American Association for Cancer Research’s Annual Meeting (“AACR 2024”). The data will be shared in a poster presentation entitled “Revitalizing Anti-Tumor Immunity Through PLT012 Monoclonal Antibody, Targeting CD36 for Metabolic Rewiring in the Tumor Microenvironment”, on April 8^th, 2024 (Abstract #2370)

CD36, a fatty acid transporter, has been reported to be up-regulated in both malignant cells and tumor-associated immune cells, including regulatory T cells, tumor-associated macrophages and CD8+ T cells, to adjust the metabolic preference, which allow the cells to adapt in the lipid-enriched tumor microenvironment (“TME”). This CD36-mediated adaption not only alters metabolic regulations, but also impacts the immune cell properties to construct an immunosuppressive TME with increased exhausted tumor-reactive CD8+ T cells and immunosuppressive regulatory T cells.

PLT012, a humanized anti-CD36 antibody, was developed to block CD36-mediated fatty acid uptake without interfering with other physiological functions. PLT012 aims to disarm intratumoral Treg and boost tumor-reactive CD8+ T cells in the tumor microenvironment, leading to remarkable anti-tumor efficacy and synergistic effects with current ICB therapies. More detailed data will be presented at AACR 2024.

Pilatus Biosciences is a Swiss/US-based R&D company spun out of Ludwig Institute for Cancer Research in 2022. Our science is rooted in the ground-breaking research of Dr. Ping-Chih Ho at the University of Lausanne on harnessing metabolic adaptations regulated or modulated by Metabolic Checkpoints to drive immunometabolic and microenvironmental reprogramming, with the aim of advancing the field of cancer immunotherapy.

For more information, please visit https://www.pilatusbio.com/ on LinkedIn .

Pilatus Biosciences

Pilatus Biosciences (the “Company”), a biotechnology company focused on d shaping the future of cancer treatment through trailblazing First-in-class biologics focusing on metabolic checkpoints, today announced that the Company will present new preclinical data of its anti-CD36 antibody program, PLT012, at the upcoming Society for Immunotherapy of Cancer’s 38^th Annual Meeting (SITC 2023). The data will be shared in a poster presentation entitled “PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment”, on November 3^rd, 2023 (Abstract #1401)

Raven Lin, PhD, MBA, Chief Executive Officer

E-mail: raven.lin@pilatusbio.com

Office line: +41 (0) 795060711

Pilatus Biosciences (the “Company”), a biotechnology company focused on d shaping the future of cancer treatment through trailblazing First-in-class biologics focusing on metabolic checkpoints, today announced that the Company will present new discovery data of its anti-PD-L1/IL10 bifunctional immunocytokine program, PLT011, at the upcoming Society for Immunotherapy of Cancer’s 38^th Annual Meeting (SITC 2023). The data will be shared in a poster presentation entitled “A novel PD-L1 antibody-IL10 fusion protein, PTL011, exhibits synergized therapeutic effect in Hepatocellular Carcinoma mouse model”, on November 4^th, 2023 (Abstract #836).